Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Lyxumia(R) (lixisenatide) in Combination With Basal Insulin Plus Oral Anti-Diabetics Significantly Reduced HbA1c and Post-Prandial Glucose
Lyxumia(R) (lixisenatide) in Combination With Basal Insulin Plus Oral Anti-Diabetics Significantly Reduced HbA1c and Post-Prandial Glucose
Lyxumia(R) (lixisenatide) in Combination With Basal Insulin Plus Oral Anti-Diabetics Significantly Reduced HbA1c and Post-Prandial Glucose
Submitted by
admin
on June 10, 2012 - 11:12am
Source:
Yahoo/MarketWire
News Tags:
lixisenatide
type 2 diabetes
diabetes
Sanofi
Headline:
Lyxumia(R) (lixisenatide) in Combination With Basal Insulin Plus Oral Anti-Diabetics Significantly Reduced HbA1c and Post-Prandial Glucose
Do Not Allow Advertisers to Use My Personal information
